Jupiter Endovascular is running a US pivotal trial on a transcatheter device that can transform along its entire length from flexible for navigation to firm as a base of operation for therapy delivery. Its first application is the treatment of pulmonary embolism, an underpenetrated $3 billion market.

The incidence of coronary artery dissections during DCB angioplasty is approximately 40%. The risk of dissection is increased when treating the left anterior descending artery and long lesions. Leaving a dissection untreated, based on a combined angiographic evaluation of TIMI flow, residual minimal lumen diameter and persistent extra-luminal contrast hang-up, is safe and does not exhibit adverse prognostic impact at 2 years.

The centralized procurement reforms under the DRG/DIP framework have significantly impacted the costs associated with Percutaneous Coronary Intervention (PCI) procedures. While there have been notable cost reductions for drug-eluting stents, these savings have been partially offset by an increased reliance on complementary devices and higher service fees. As a result, the overall procedural costs have risen, illustrating the complexity of managing expenses in this new healthcare environment. The interplay between lower device prices and additional costs for necessary adjuncts highlights the challenges faced by hospitals in maintaining cost-effectiveness while ensuring quality care.

SMT’s Chief Medical Officer Dr Krishna Sudhir commented, “This study confirms the benefits of using Supraflex Cruz in an all-comers population, with excellent outcomes for the complex subsets of patients. With ever more challenging morphology for clinicians to treat, this provides an important option for these patients and further adds to the large body of evidence for Supraflex Cruz.”

Many lines of evidence support the interplay of autophagy with AA availability and metabolism in atherosclerosis. Recent findings have provided new insights into the pathogenesis of atherosclerosis, which is not just a disease characterized by lipid accumulation in the blood vessels but rather a chronic inflammatory disease. This evolving understanding points to the importance of immune cells and their interaction with non-immune cells in the progression of atherosclerosis. The activation of effective autophagy in cell types involved in atherogenesis plays a protective role in reducing atherosclerosis development and maintaining plaque stability. While the canonical biological role of AAs in protein synthesis is clear, they can affect intracellular metabolism, autophagy, and consequently atherogenesis in many different ways.

The burden of coronary in-stent restenosis (ISR) remains a significant clinical challenge. Even with contemporary drug-eluting stent (DES) placement, target lesion revascularization (TLR) occurs at a rate of 2% in the first and in each subsequent year, with TLR occurring after 2 years in nearly half of all patients.1,2 Moreover, ≥10% of the patients who experience ISR will go on to develop recurrent ISR, an even more vexing problem.2 Over the past decade, approximately 10% of all percutaneous coronary interventions in the United States have been for ISR, which has been linked to a greater risk of major adverse cardiac events (MACEs) than have percutaneous coronary interventions for de novo lesions.2 The mechanisms behind ISR are varied, making its management complex.

Medical specialists consider stent placement when medications or lifestyle changes are not so effectively controlling symptoms or when a patient has very severe symptoms that place him at immediate risk of having a heart attack. A common scenario where a stent must be placed includes: Severe chest pain (unstable angina): If the pain is frequent, lasts longer, or just starts to occur at rest, it may indicate that an artery is very narrow or nearly closed, so a stent might be required Obstruction of coronary arteries: If the diagnostic observations point out that the coronary artery is severely narrowed and the heart muscle is likely to get damaged or hurt, then further treatments such as stenting will be needed Postmyocardial infarction: The interruption of blood flow within a heart section can lead to a heart attack. Restoring the supply of blood to that area as soon as possible after an emergency stenting procedure can prevent extensive heart damage caused by the attack.

Our study provides one of the first successful examples of prevention of neointimal hyperplasia after stent placement with a simple orally given treatment of well-tolerated Provinols™ in rabbit fed with a high-cholesterol diet. This may open a new avenue for further animal experimentations and clinical studies. The reduction of neointimal hyperplasia is indeed interesting by itself, even though further studies are needed to better understanding the underlying mechanisms. Nevertheless, the potential of the compound studied here deserves attention because if clinical studies confirm these observations, the anticipated reduction in costs will be dramatic. This study suggests a basis for the beneficial effects of red wine polyphenols against in-stent restenosis and provides robust arguments to explain the benefits linked to the Mediterranean diet.

Ultrasonic stent coating system is an ultrasonic spray coating system specially used for deposition of drug layers on stents. The ultrasonic stent coating system is equipped with Siansonic NanoMist ultrasonic nozzle or FocusMist ultrasonic nozzle to deposit drug coating onto the stent surface through ultrasonic atomization technology. It can precisely control the dosage of the coating, and the coating is uniform without adhesion, pinholes, orange peel and other defects. It can be used for depositing drug coating on coronary stents, peripheral stents, sinus stents, intracranial stents and other stents.

We developed a novel process to coat expandable coronary stents, producing a sutureless coating that expanded by 150% without tearing or delaminating. Tensile testing the coating material showed that the polymer maintains complete mechanical integrity in fibrous form following maximal expansion.

The evolution of endovascular therapies, particularly in the field of intracranial aneurysm treatment, has been truly remarkable and is characterized by the development of various stents. However, ischemic complications related to thrombosis or downstream emboli pose a challenge for the broader clinical application of such stents. Despite advancements in surface modification technologies, an ideal coating that fulfills all the desired requirements, including anti-thrombogenicity and swift endothelialization, has not been available. To address these issues, we investigated a new coating comprising 3-aminopropyltriethoxysilane (APTES) with both anti-thrombogenic and cell-adhesion properties.

By exploring new biomass sources and improving the preparation process or surface modification, B-CDs can be made to have anti-inflammatory, endothelialization-promoting, anticoagulation, and fluorescence imaging properties, which will play an important role in the application of vascular stents. Although B-CDs show extraordinary potential in the coating of vascular stents, there may be some challenges in practical applications, such as ensuring coating uniformity, long-term stability, and the feasibility of large-scale production.

Unlike traditional PCI technologies, the bioadaptor leverages a unique mechanism of action that is designed to restore vessel motion and function by unlocking its helical strands after six months to provide adaptive, dynamic support to help the vessel better respond to the body’s physiological demands. Bioadaptor has been used to treat thousands of patients to date and has growing physician experience in complex PCI cases, including primary PCI, chronic total occlusions (CTOs), bifurcations, and calcified lesions.

"The results from the post-PCI assessments performed on patients who underwent PCI and OMT, planned to be analyzed and reported after the completion of one-year follow-up, can provide the very much needed insight on optimal cut-off(s) for post-PCI FFR values, and provide the clinical evidence necessary to encourage routine post-PCI physiology assessment. The results of this study are groundbreaking for coronary artery disease diagnostics in Japan. FFRangio offers a non-invasive alternative that not only matches the diagnostic accuracy of traditional wire-based FFR but also improves operational efficiencies and reduces costs for healthcare providers.”

Abbott recently announced new data for the Amplatzer Amulet Left Atrial Appendage (LAA) Occluder to treat people with atrial fibrillation (AFib) who are at an increased risk of stroke. The new five-year findings demonstrate that Abbott's Amplatzer Amulet helps more patients avoid long-term use of blood-thinning medication compared to the Watchman device.

ADVANCE-DK is data from a subset of the larger ADVANCE registry, which prospectively evaluated the use of a coronary computed tomography angiography (CCTA) and FFRCT diagnostic pathway in real-world settings to determine the impact on decision-making, downstream invasive coronary angiography (ICA), revascularisation, and major adverse cardiovascular events (MACE). ADVANCE-DK assessed three patient sets: those with normal FFRCT, those with subsequent complete revascularization (CR), and those with subsequent incomplete revascularisation (IR).

Valvosoft is designed to non-invasively restore leaflet mobility in a stenotic aortic valve and widen the valve opening to relieve patient heart failure symptoms. High-intensity focused ultrasound waves micro-fracture calcification embedded in aortic valve leaflets without damaging tissue. The treatment is designed to be repeatable over time, as needed, to manage disease progression.

The largest trial to date to study the impact of colchicine—an anti-inflammatory medicine commonly used to treat gout—in acute myocardial infarction (MI) has found that administering a low dose of the drug did not reduce cardiovascular death, MI, stroke or ischaemia-driven revascularisation compared to placebo.

“The cardiology community has long sought solutions that can better treat patients with calcified lesions to achieve optimal percutaneous coronary intervention (PCI) outcomes,” said Johan Bennett (University Hospital Leuven, Leuven, Belgium) PINNACLE I principal investigator. “The six-month PINNACLE I data are a strong validation of LithiX IVL’s mechanism of action that can safely fragment calcium across a range of complex morphologies without trauma to the soft tissue and can be easily integrated into standard PCI procedure workflow without the need for an energy source.”

Using the most conservative delta between the two groups in terms of the primary efficacy endpoint at 365 days, not inclusive of the treatment window, the Esprit BTK scaffold costs an additional US$7,086 per primary efficacy endpoint avoided. This led Parikh to report that the Esprit BTK scaffold achieves a 64% probability of cost-effectiveness at a US$10,000 willingness-to-pay threshold compared to angioplasty. As a result of this, he averred: “The use of Esprit BTK at one year alone is likely to be cost effective.”